Outcome of high (200 mg/m2)/modified (100–140 mg/m2) dose melphalan followed by peripheral blood stem cell transplantation (PBSCT).*
| Patients Treated . | HDM 200 mg/m2 . | TRM# . | Clonal Response (partial + complete) . | Complete Response . | Organ Response . | Organ Resp./ Clonal Resp. . | Center, Year, Reference . |
|---|---|---|---|---|---|---|---|
| *Studies reporting 20 or more patients published in year 2000 or later are listed | |||||||
| #Treatment-related mortality within 100 days from melphalan administration | |||||||
| § Organ response was listed according to organs and not to patients (renal 46%, cardiac 25%, liver 50%, neurologic 0%) | |||||||
| ‡ Study performed at the Pavia Amyloidosis Centre and at the National Cancer Institute, Milan, data unpublished. | |||||||
| †After new selection criteria and prophylactic measures were introduced in January 1999, TRM decreased from 50% (5/10) to 20% (2/10) | |||||||
| ¥Includes consecutive patients from 6 separate trials over 8 years, please note that 122 patients received an intermediate dose of melphalan (100–140 mg/m2) | |||||||
| ** Hematologic response was evaluated at 1 year: in 39 patients 1 year had not passed since treatment | |||||||
| Abbreviations: HDM, high-dose melphalan; TRM, treatment-related mortality; NR, not reported | |||||||
| 66 | 38 | 9/66 (14%) | 33/66 (50%) | NR | 32/66 (48%) | 23/33 (70%) | Single center, 20024 |
| 22 | 14 | 3/22 (14%) | 13/22 (59%) | 8/22 (36%) | 10/22 (45%) | 10/13 (77%) | Two-centers, 2004‡ |
| 20 | 9 | 7/20 (35%)† | 56% | 28% | § | NR | Single center, 200420 |
| 277¥ | 155 | 36/277 (13%) | NR | 73/238 (31%)** | 80/238 (34%) | 48/73 (66%) | Single center, 20043 |
| Patients Treated . | HDM 200 mg/m2 . | TRM# . | Clonal Response (partial + complete) . | Complete Response . | Organ Response . | Organ Resp./ Clonal Resp. . | Center, Year, Reference . |
|---|---|---|---|---|---|---|---|
| *Studies reporting 20 or more patients published in year 2000 or later are listed | |||||||
| #Treatment-related mortality within 100 days from melphalan administration | |||||||
| § Organ response was listed according to organs and not to patients (renal 46%, cardiac 25%, liver 50%, neurologic 0%) | |||||||
| ‡ Study performed at the Pavia Amyloidosis Centre and at the National Cancer Institute, Milan, data unpublished. | |||||||
| †After new selection criteria and prophylactic measures were introduced in January 1999, TRM decreased from 50% (5/10) to 20% (2/10) | |||||||
| ¥Includes consecutive patients from 6 separate trials over 8 years, please note that 122 patients received an intermediate dose of melphalan (100–140 mg/m2) | |||||||
| ** Hematologic response was evaluated at 1 year: in 39 patients 1 year had not passed since treatment | |||||||
| Abbreviations: HDM, high-dose melphalan; TRM, treatment-related mortality; NR, not reported | |||||||
| 66 | 38 | 9/66 (14%) | 33/66 (50%) | NR | 32/66 (48%) | 23/33 (70%) | Single center, 20024 |
| 22 | 14 | 3/22 (14%) | 13/22 (59%) | 8/22 (36%) | 10/22 (45%) | 10/13 (77%) | Two-centers, 2004‡ |
| 20 | 9 | 7/20 (35%)† | 56% | 28% | § | NR | Single center, 200420 |
| 277¥ | 155 | 36/277 (13%) | NR | 73/238 (31%)** | 80/238 (34%) | 48/73 (66%) | Single center, 20043 |